Inflammatory molecules might become both biomarkers and therapeutic targets for stroke management

Laura Ramiro, Alba Simats, Teresa García-Berrocoso, Joan Montaner

    Research output: Contribution to journalReview articleResearchpeer-review

    54 Citations (Scopus)


    © The Author(s), 2018. Stroke is the fifth leading cause of death and the most frequent cause of disability worldwide. Currently, stroke diagnosis is based on neuroimaging; therefore, the lack of a rapid tool to diagnose stroke is still a major concern. In addition, therapeutic approaches to combat ischemic stroke are still scarce, since the only approved therapies are directed toward restoring blood flow to the affected brain area. However, due to the reduced time window during which these therapies are effective, few patients benefit from them; therefore, alternative treatments are urgently needed to reduce stroke brain damage in order to improve patients’ outcome. The inflammatory response triggered after the ischemic event plays an important role in the progression of stroke; consequently, the study of inflammatory molecules in the acute phase of stroke has attracted increasing interest in recent decades. Here, we provide an overview of the inflammatory processes occurring during ischemic stroke, as well as the potential for these inflammatory molecules to become stroke biomarkers and the possibility that these candidates will become interesting neuroprotective therapeutic targets to be blocked or stimulated in order to modulate inflammation after stroke.
    Original languageEnglish
    JournalTherapeutic Advances in Neurological Disorders
    Publication statusPublished - 1 Jan 2018


    • biomarkers
    • cerebrovascular disease
    • inflammation
    • neuroprotection
    • stroke
    • therapeutic targets


    Dive into the research topics of 'Inflammatory molecules might become both biomarkers and therapeutic targets for stroke management'. Together they form a unique fingerprint.

    Cite this